Charles Schwab Investment Management Inc Eagle Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 73,927 shares of EGRX stock, worth $413,991. This represents 0.0% of its overall portfolio holdings.
Number of Shares
73,927
Previous 72,282
2.28%
Holding current value
$413,991
Previous $378,000
2.38%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding EGRX
# of Institutions
94Shares Held
10.4MCall Options Held
3KPut Options Held
36.3K-
Nantahala Capital Management, LLC New Canaan, CT1.26MShares$7.05 Million0.42% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.19MShares$6.64 Million2.51% of portfolio
-
Black Rock Inc. New York, NY898KShares$5.03 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT879KShares$4.92 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA641KShares$3.59 Million0.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $72.9M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...